Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults

Completed

• Conditions: Cystic Fibrosis
• Interventions: Behavioral: Questionnaires

• Registration Number: NCT03659214
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The aim of this project is to evaluate the psychological reshuffle induced by ORKAMBI. The particular focus of this study is the consequence of its introduction on anxiety, depression, quality of life and adherence to all cystic fibrosis (CF) treatment. To answer this question investigators will monitor the psychological function of CF adolescents and young adults treated with ORKAMBI and compare them to CF adolescents and young adults not treated with ORKAMBI.

Detailed Description

Introduction of KALYDECO then ORKAMBI, as a personalized medicine in the therapeutic strategy of Cystic Fibrosis (CF) may deeply modify the prognosis of patients with CF. These approaches realize the dream of short-circuiting the molecular mechanism of the disease and therefore opens the perspective of an extended and functional survival. It suddenly offers the possibility of a completely new future to the patient and his family, and therefore must deeply impact on the psychological function of all involved. Moreover, those new therapies may also modify the adherence to CF basic treatment, as it brings a new feeling of good health and the hope of a longer life. For that reason there is a need to investigate modifications of the psychological state of mind induced by the treatment with ORKAMBI in CF adolescents and young adults.

This project aims to understand the psychological impact and to study the consequences of the introduction of ORKAMBI on adherence to CF treatment, anxiety, depression and quality of life.

To answer this question, investigators will evaluate the psychological function of adolescents and young adults, aged 12 to 20 years, with CF treated with ORKAMBI, and compare it to other adolescents and young CF adults not treated with ORKAMBI.

This is a cohort prospective study, with a 1 year follow-up.

Study Timeline

• Study Start: 2017-12-01
• Study First Submitted: 2018-09-03
• Study First Submitted QC: 2018-09-03
• Study First Posted: 2018-09-06
• Primary Completion: 2022-01-19
• Study Completion: 2022-01-19
• Status Verified: 2022-10
• Last Update Submitted: 2023-02-02
• Last Update Posted: 2023-02-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Treated group: Patients with proven CF (sweat-test > 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI
• Control group: Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco

Exclusion Criteria

• Transplanted patients
• Patients younger than 12 years
• Patients older than 20 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control group	Questionnaires	Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
Treated group	Questionnaires	Patients with proven CF (sweat-test \> 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)

Primary Outcome Measures

Name	Time	Method
Score of Generalized Anxiety Disorder-7 questionnaire (GAD-7)	24 months	to assess the impact on Anxiety

Secondary Outcome Measures

Name	Time	Method
Scores of Cystic Fibrosis Questionnaire 14+ (CFQ 14+)	24 months	Disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms (Quality of Life)
GIRERD Scale	24 months	The 6 items are assessed using a YES/NO answer .The scale was validated in patients with chronic disease to assess medication adherence
Score of Patient Health Questionnaire-9 (PHQ-9 )	24 months	To assess the impact on Depression

Trial Locations

Locations (1)

Department of Pneumology -CRCM - Necker - Enfants maladies Hospital (AP-HP); 🇫🇷 Paris, France